Log in

NASDAQ:EVFM - Evofem Biosciences Stock Price, Forecast & News

-0.17 (-2.56 %)
(As of 02/24/2020 07:20 AM ET)
Today's Range
Now: $6.46
50-Day Range
MA: $5.51
52-Week Range
Now: $6.46
Volume79,374 shs
Average Volume76,846 shs
Market Capitalization$302.39 million
P/E RatioN/A
Dividend YieldN/A
Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EVFM



Sales & Book Value

Annual SalesN/A
Book Value($0.90) per share


Net Income$-125,710,000.00


Market Cap$302.39 million
Next Earnings Date3/6/2020 (Estimated)
OptionableNot Optionable

Receive EVFM News and Ratings via Email

Sign-up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.

Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions

What is Evofem Biosciences' stock symbol?

Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."

How were Evofem Biosciences' earnings last quarter?

Evofem Biosciences Inc (NASDAQ:EVFM) issued its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.01. View Evofem Biosciences' Earnings History.

When is Evofem Biosciences' next earnings date?

Evofem Biosciences is scheduled to release their next quarterly earnings announcement on Friday, March 6th 2020. View Earnings Estimates for Evofem Biosciences.

What price target have analysts set for EVFM?

3 brokerages have issued 12 month price targets for Evofem Biosciences' stock. Their forecasts range from $9.00 to $11.00. On average, they anticipate Evofem Biosciences' share price to reach $10.33 in the next twelve months. This suggests a possible upside of 60.0% from the stock's current price. View Analyst Price Targets for Evofem Biosciences.

What is the consensus analysts' recommendation for Evofem Biosciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evofem Biosciences.

Has Evofem Biosciences been receiving favorable news coverage?

Media stories about EVFM stock have trended very negative recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evofem Biosciences earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Evofem Biosciences.

Are investors shorting Evofem Biosciences?

Evofem Biosciences saw a increase in short interest in January. As of January 31st, there was short interest totalling 797,900 shares, an increase of 7.7% from the January 15th total of 740,600 shares. Based on an average daily trading volume, of 89,500 shares, the short-interest ratio is currently 8.9 days. Currently, 2.5% of the company's shares are sold short. View Evofem Biosciences' Current Options Chain.

Who are some of Evofem Biosciences' key competitors?

What other stocks do shareholders of Evofem Biosciences own?

Who are Evofem Biosciences' key executives?

Evofem Biosciences' management team includes the folowing people:
  • Ms. Saundra Pelletier, CEO & Director
  • Mr. Justin J. File, Chief Financial Officer (Age 49)
  • Dr. Kelly Culwell, Chief Medical Officer
  • Mr. Jason Abrams, Accounting Mang.
  • Mr. Alexander A. Fitzpatrick, Exec. VP, Gen. Counsel & Sec. (Age 52)

Who are Evofem Biosciences' major shareholders?

Evofem Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Link Fund Solutions Ltd (19.52%), Schroder Investment Management Group (7.17%), State Street Corp (0.60%), Geode Capital Management LLC (0.56%), Bank of Montreal Can (0.20%) and Renaissance Technologies LLC (0.10%). Company insiders that own Evofem Biosciences stock include Alexander A Fitzpatrick, Justin J File, Kelly Culwell, Kim P Kamdar, Ltd Invesco, Pdl Biopharma, Inc, Russell Barrans, Saundra L Pelletier and Thomas G Lynch. View Institutional Ownership Trends for Evofem Biosciences.

Which institutional investors are selling Evofem Biosciences stock?

EVFM stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC. Company insiders that have sold Evofem Biosciences company stock in the last year include Justin J File, Kelly Culwell, Kim P Kamdar, Russell Barrans and Saundra L Pelletier. View Insider Buying and Selling for Evofem Biosciences.

Which institutional investors are buying Evofem Biosciences stock?

EVFM stock was bought by a variety of institutional investors in the last quarter, including Link Fund Solutions Ltd, Schroder Investment Management Group, Bank of Montreal Can, State Street Corp, Renaissance Technologies LLC, Tocqueville Asset Management L.P., Barclays PLC and UBS Group AG. Company insiders that have bought Evofem Biosciences stock in the last two years include Alexander A Fitzpatrick, Kelly Culwell, Ltd Invesco, Pdl Biopharma, Inc, Russell Barrans, Saundra L Pelletier and Thomas G Lynch. View Insider Buying and Selling for Evofem Biosciences.

How do I buy shares of Evofem Biosciences?

Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Evofem Biosciences' stock price today?

One share of EVFM stock can currently be purchased for approximately $6.46.

How big of a company is Evofem Biosciences?

Evofem Biosciences has a market capitalization of $302.39 million. The biotechnology company earns $-125,710,000.00 in net income (profit) each year or ($5.74) on an earnings per share basis. Evofem Biosciences employs 30 workers across the globe.View Additional Information About Evofem Biosciences.

What is Evofem Biosciences' official website?

The official website for Evofem Biosciences is http://www.evofem.com/.

How can I contact Evofem Biosciences?

Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]

MarketBeat Community Rating for Evofem Biosciences (NASDAQ EVFM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  197 (Vote Underperform)
Total Votes:  423
MarketBeat's community ratings are surveys of what our community members think about Evofem Biosciences and other stocks. Vote "Outperform" if you believe EVFM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVFM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: Debt-To-Equity Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel